Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Figure 3

Funnel plot for the comparison of the incidence of neoplasia with the use of GLP-1 receptor agonists versus placebo or other antidiabetic treatments.